Current Activities

中文 | English | 2012年10月02日

Mission
Contacts Us
Members
Links
Researches
Current Activities
Special Focuses

 

  1. 2011/06/15

    • The phase III study “A randomized, open-label study to compare the efficacy and safety of AT1001 and enzyme replacement therapy (ERT) in patients with Fabry disease and AT1001-reponsive GLA mutation, who were previously treated with ERT” cooperated with Amicus therapeutics

  2. 2011/07/22

    • The phase III study cooperated with Amicus therapeutics was revised and approved by IRB committee.

  3. 2011/11/22

    • The NRPB project was approved.

  4. 2011/11/26

    • The study of “International observational case review of efficacy and safety of switch between agalsidase beta to agalsidase alfa for enzyme replacement in males and females with Anderson-Fabry Disease” in cooperation with Dr. Rolfs, Rostock University, Germany is under examination by IRB committee of VGH-TPE.

  5. 2012/02/06

    • The  study “Fabry Outcome Survey, FOS” collaborated with  Shire Inc. USA has been approved by IRB committee of VGH-TPE.

  6. 2012/2/22

    • The Website of Taiwan Clinical Trial Consortium in Fabry Disease was started.

 

首頁 | Mission | Contacts Us | Members | Links | Researches | Current Activities | Special Focuses

上次修改此網站的日期: 2012年10月02日